Last reviewed · How we verify
NCT07376694
Improving Uptake of Bowel Cancer Screening Among South Asian Adults in Bradford
NA trial testing Bowel cancer screening kit in Bowel Cancer Screening in 2,300 participants. Participants enrolled and being followed up; not accepting new ones.
1 April 2026
Quick facts
| Lead sponsor | University of Hull |
|---|---|
| Phase | NA |
| Status | Active, enrolled |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | screening |
| Enrollment | 2,300 |
| Start date | 1 November 2024 |
| Primary completion | 1 April 2026 |
| Estimated completion | 30 June 2026 |
| Sites | 1 location across United Kingdom |
Drugs / interventions tested
- Bowel cancer screening kit
Conditions studied
- Bowel Cancer Screening — all drugs for Bowel Cancer Screening →
Sponsor
University of Hull
Who can join
50 and older, any sex, with Bowel Cancer Screening. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Bowel cancer is the second most common cause of cancer related deaths in England. Bowel cancer screening can reduce bowel cancer deaths by detecting bowel cancer early. Previous research has shown that screening can lower a person's risk of dying from bowel cancer by over 25%. In England, the NHS offers free bowel cancer screening for adults aged 60 - 74 years who are registered with a GP every two years, but screening uptake remains poor among those in deprived areas and amongst minority ethnic groups. In socioeconomically deprived areas like Bradford, where there is a high proportion of South Asian residents, bowel cancer screening uptake is low compared to other parts of England. The investigators previous research has shown that people of South Asian ethnicity are limited by many factors beyond language barriers and thus require culturally tailored approaches to facilitate uptake. For this study, the investigators will aim to answer the question: 'Does a culturally tailored enhanced screening kit, comprising an instruction letter and booklet, and a bio-degradable poo catcher increase bowel cancer screening uptake among South Asians living in Bradford?'. Over a 6-month period, individuals registered in 17 GP practices in Bradford and due to receive their NHS bowel cancer screening invitation will be assigned to two groups: standard kit (usual screening kit only) and enhanced kit (culturally tailored instruction letter and biodegradable poo catcher). Uptake of bowel cancer screening among South Asian participants in each group will be assessed 13 weeks after the identification of the final participant. The findings of this study will provide valuable information for policy makers about how to address population specific barriers to bowel cancer screening using culturally tailored approaches in the UK.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07376694
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other University of Hull trials
Trials by the same sponsor.
- NCT05646199 — Semaglutide vs Metformin in Polycystic Ovary Syndrome (PCOS) · Phase 2, PHASE3 · not yet recruiting
- NCT06276686 — Exercise for Improving Long-course Chemoradiotherapy Efficacy in People With Locally Advanced Rectal Cancer · EARLY_PHASE1 · recruiting
- NCT07299682 — Facilitating Effective Eating With DoddleBags: A Single-Arm Acceptability Study Of DoddleBags to Assess Impact on Self F · NA · recruiting
- NCT06595316 — Exercise for Ameliorating Chemotherapy Cardiotoxicity · NA · not yet recruiting
- NCT06292975 — Exercise for Improving Radiotherapy Efficacy in Rectal Cancer · NA · withdrawn
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07376694 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Hull
- Last refreshed: 29 January 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07376694.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing